These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34187344)

  • 1. Evaluation of synergistic activity of plazomicin-based combinations against KPC-producing
    Iannaccone M; Boattini M; Bianco G; Cavallo R; Costa C
    J Chemother; 2022 Feb; 34(1):71-72. PubMed ID: 34187344
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
    Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species.
    Haidar G; Alkroud A; Cheng S; Churilla TM; Churilla BM; Shields RK; Doi Y; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5208-14. PubMed ID: 27297487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARGONAUT II Study of the
    Jacobs MR; Good CE; Hujer AM; Abdelhamed AM; Rhoads DD; Hujer KM; Rudin SD; Domitrovic TN; Connolly LE; Krause KM; Patel R; Arias CA; Kreiswirth BN; Rojas LJ; D'Souza R; White RC; Brinkac LM; Nguyen K; Singh I; Fouts DE; van Duin D; Bonomo RA;
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae.
    Tascini C; Tagliaferri E; Giani T; Leonildi A; Flammini S; Casini B; Lewis R; Ferranti S; Rossolini GM; Menichetti F
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3990-3. PubMed ID: 23752510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Clinical Cases of KPC-2-Producing
    Brahmia S; Lalaoui R; Nedjai S; Djahmi N; Chettibi S; Rolain JM; Bakour S
    Microb Drug Resist; 2021 May; 27(5):652-659. PubMed ID: 32991248
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of the mcr-1 gene by a high-risk clone of KPC-2-producing Klebsiella pneumoniae ST437/CC258, Brazil.
    Dalmolin TV; Martins AF; Zavascki AP; de Lima-Morales D; Barth AL
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):132-133. PubMed ID: 29169659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Dissemination of IncQ1 Plasmids in KPC-2-Producing
    Campos PA; Fuga B; Cerdeira LT; Ferreira ML; Dias VL; Machado LG; Rossi I; Lincopan N; Gontijo-Filho PP; Ribas RM
    Microb Drug Resist; 2019 Oct; 25(8):1257-1259. PubMed ID: 31188044
    [No Abstract]   [Full Text] [Related]  

  • 16. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ; Lai CC; Chen CC; Zhang CC; Weng TC; Chiu YH; Toh HS; Chiang SR; Yu WL; Ko WC; Chuang YC
    J Microbiol Immunol Infect; 2019 Apr; 52(2):273-281. PubMed ID: 27133391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
    Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
    Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G
    J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
    Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
    Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin.
    Clancy CJ; Chen L; Hong JH; Cheng S; Hao B; Shields RK; Farrell AN; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5258-65. PubMed ID: 23939888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.